I期肺癌的最佳淋巴结检查数目与辅助化疗
基于美国国家癌症数据库2006至2014年手术治疗的病理I期肺癌患者65,438例,确定T1a、T1b、T1c、T2a分别需检查8、9、10、11枚淋巴结;临床I期队列117,112例验证该阈值可独立预测淋巴结分期上调(OR=1.706,95%CI 1.608-1.779)和生存(HR=0.890,95%CI 0.865-0.916);倾向匹配后辅助化疗仅与T2a且分期不充分患者生存改善相关(HR=0.841,95%CI 0.714-0.990)。
要点
- T1a、T1b、T1c、T2a分别检查8、9、10、11枚淋巴结与生存获益相关。
- 8至11枚淋巴结阈值可独立预测淋巴结分期上调(OR=1.706,95%CI 1.608-1.779)。
- 辅助化疗仅与T2a且淋巴结分期不充分患者生存改善相关(HR=0.841,95%CI 0.714-0.990)。
核心结论
- 淋巴结评估对准确分期和充分治疗重要,随T分期增高检查8、9、10、11枚淋巴结似乎对预测分期上调和生存结局至关重要。
- 辅助化疗可能对淋巴结分期不充分的T2a期患者有益。
研究设计与样本
- 查询美国国家癌症数据库2006至2014年手术治疗的病理I期肺癌患者65,438例,确定最佳淋巴结检查数目。
- 在临床I期肺癌患者117,112例队列中,从淋巴结分期上调和预后分层方面验证最佳淋巴结数目。
- 在各T分期中评估淋巴结分期不充分(检查淋巴结数少于最佳值)患者接受辅助化疗的作用。
主要发现
- 检查淋巴结数与肿瘤大小相关(p < 0.001)。
- 每增加一枚淋巴结检查,生存获益增加,T1a、T1b、T1c、T2a患者分别最多至8、9、10、11枚。
- 临床分期队列验证显示,8至11枚淋巴结阈值是淋巴结分期上调的独立预测因素(OR=1.706,95%CI 1.608-1.779)和生存结局的独立预测因素(HR=0.890,95%CI 0.865-0.916)。
- 倾向匹配后,辅助化疗与T2a期且淋巴结分期不充分患者的生存改善相关(HR=0.841,95%CI 0.714-0.990),但与T1a至T1c期患者无关。
关键数值与推荐
- T1a、T1b、T1c、T2a期患者最佳淋巴结检查数目分别为8、9、10、11枚。
- 8至11枚淋巴结阈值预测淋巴结分期上调的OR=1.706(95%CI 1.608-1.779)。
- 8至11枚淋巴结阈值预测生存结局的HR=0.890(95%CI 0.865-0.916)。
- T2a期且淋巴结分期不充分患者辅助化疗的HR=0.841(95%CI 0.714-0.990)。
临床怎么用
- 作者认为,淋巴结评估对准确分期和充分治疗重要,随T分期增高检查8、9、10、11枚淋巴结似乎对预测分期上调和生存结局至关重要。
- 作者认为,辅助化疗可能对淋巴结分期不充分的T2a期患者有益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the optimal number of lymph nodes (LNs) examined and the role of adjuvant chemotherapy in stage I lung cancer. METHODS: The National Cancer Database was queried for surgically treated patients with pathologic stage I lung cancer between 2006 and 2014 (N = 65,438). The optimal LN numbers were determined in the multivariate Cox model and were further validated in the cohort with clinical stage I disease (N = 117,112) in terms of nodal upstaging and prognostic stratification. The role of adjuvant chemotherapy in patients with suboptimal staging (number of LNs examined was less than than the optimum) was evaluated in each T stage. RESULTS: The number of LNs examined correlated with tumor size (p < 0.001). There were increasing survival benefits with each additional LN examined-up to eight, nine, 10, and 11 nodes for patients with T1a, T1b, T1c, and T2a, respectively. Validation from the cohort with clinically staged disease showed that the threshold of eight to 11 LNs was an independent predictor of nodal upstaging (OR = 1.706, 95% confidence interval [CI] 1.608-1.779) and survival outcome (hazard ratio = 0.890, 95% CI: 0.865-0.916). After propensity matching, adjuvant chemotherapy was associated with improved survival in patients with stage T2a disease having suboptimal staging (hazard ratio = 0.841, 95% CI: 0.714-0.990), but not in patients with stage T1a to T1c disease. CONCLUSION: LN evaluation was important for accurate staging and adequate treatment, and examinations of an increasing number of nodes for progressively higher T components (i.e., eight, nine, 10, and 11 nodes for T1a, T1b, T1c, and T2a tumors, respectively) seemed crucial to predict upstaging and survival outcomes. Adjuvant chemotherapy might be beneficial to patients with stage T2a disease who have suboptimal nodal staging.
引用
- Dai J, Liu M, Yang Y, et al. Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer. J Thorac Oncol. 2019. PMID: 31009811. doi:10.1016/j.jtho.2019.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。